Motor performance and functional exercise capacity in survivors of pediatric acute lymphoblastic leukemia
- 28 June 2012
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 60 (3) , 494-499
Abstract
Background: Impaired motor performance and reduced maximum exercise capacity during and after treatment of acute lymphoblastic leukemia (ALL) has been shown. However, no longitudinal study monitoring motor performance after cessation of treatment has been published. Whether sub‐maximal exercise capacity is reduced is unknown.Procedure: Motor performance of pediatric ALL survivors, treated with Dutch Childhood Oncology Group ALL‐9 protocol was measured with the movement‐ABC at stop treatment and ≥5 years later. At follow‐up functional exercise capacity was also investigated using the 6‐minute walk test (6MWT). Heart rate and oxygen saturation were measured with a portable pulse oximeter before and after the 6MWT.Results: Nineteen boys and 15 girls, median age 12.3 years (range: 9.0–18.7), median time since completion of chemotherapy 5.2 years (5.0–7.1), participated. Mean height/age and weight/age were within the norm, whereas mean BMI/age was significantly increased (mean SDS 0.38, SEM 0.17, P = 0.04). Motor performance had improved significantly (P = 0.001). In contrast, functional exercise capacity at follow‐up was significantly impaired (mean SDS −2.05, SEM 0.13, P < 0.001).Conclusions: At ≥5 years after completion of ALL treatment motor performance had improved significantly, but functional exercise capacity was significantly impaired. The exact underlying cause of this late effect needs further study. Pediatr Blood Cancer 2013; 60: 494–499.Keywords
This publication has 39 references indexed in Scilit:
- A randomized trial investigating an exercise program to prevent reduction of bone mineral density and impairment of motor performance during treatment for childhood acute lymphoblastic leukemiaPediatric Blood & Cancer, 2009
- Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristineCancer, 2006
- Strength and functional mobility in children with acute lymphoblastic leukemiaMedical and Pediatric Oncology, 2003
- Short‐term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasoneClinical Endocrinology, 2002
- Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemiaThe Journal of Pediatrics, 2002
- Osteonecrosis as a Complication of Treating Acute Lymphoblastic Leukemia in Children: A Report From the Children’s Cancer GroupJournal of Clinical Oncology, 2000
- Motor performance of children during treatment for acute lymphoblastic leukemiaMedical and Pediatric Oncology, 1999
- Bone mineral density in children with acute lymphoblastic leukaemiaEuropean Journal of Cancer, 1999
- Re: “Letter to the editor: Increased risk of cardiac dysfunction after anthracyclines in girls”Medical and Pediatric Oncology, 1995
- Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in ChildhoodNew England Journal of Medicine, 1991